• Sangamo Announces Completion Of TxCell Acquisition

    • December 6, 2018
    • Posted By : admin
    • 0 Comment
    •   71 views

    “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO of Sangamo. “We’re thrilled to work with our colleagues in France toward an exciting new future together developing CAR-Tregs. By combining Sangamo’s zinc finger nuclease gene editing technology with TxCell’s CAR-Treg platform, we have the potential to develop a pipeline of novel cell therapies for patients suffering from autoimmune and inflammatory disorders.”

    In 2019, Sangamo expects to submit a clinical trial authorization application (CTA) in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant.

  71 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!